Abstract
Objective: Free fatty acid inhibition with trimetazidine (TMZ) improves myocardial metabolism and myocardial ischemia in patients with coronary artery disease (CAD). Because of its effect on myocardial glucose utilization TMZ may represent a therapeutic option in diabetic patients with CAD. Aim of the present study was to evaluate whether the metabolic effect of TMZ may improve episodes of myocardial ischemia in diabetic patients with CAD. Research design and methods: We assessed the effect of TMZ on 24 h ambulatory ECG monitoring (AEM) in 30 patients (22 males and 8 females, mean (SE) age 67 ± 6.5 years) with NIDDM and ischemic cardiomyopathy. Patients were randomized to receive on top of standard therapy either TMZ (20 mg, tds) or placebo (tds) and were evaluated at baseline and after 6 months. Results: Patients randomized to TMZ or placebo were comparable regarding demographic data, distribution of CAD, and glicated haemoglobin levels. TMZ significantly reduced the number of episodes of transient myocardial ischemia (- 24% compared to baseline, p <0.01; - 27% compared to placebo, p <0.01), and Total Ischemic Burden (- 28% compared to baseline, p <0.01; - 29% compared to placebo, p <0.01). TMZ also significantly reduced the number of silent episodes of myocardial ischemia (- 42% compared to baseline and - 39% compared to placebo, p <0.01) and the time of silent myocardial ischemia/24 h (- 37% compared to baseline and - 35% compared to placebo, p <0.01). No significant changes in heart rate were detected between baseline, placebo and TMZ evaluations. Conclusions: TMZ is effective in reducing silent and symptomatic episodes of transient myocardial ischemia in diabetic patients with CAD on standard anti-anginal therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 79-84 |
| Number of pages | 6 |
| Journal | International Journal of Cardiology |
| Volume | 120 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Aug 9 2007 |
Fingerprint
Keywords
- Diabetes mellitus
- Myocardial ischema
- Prognosis
- Therapy
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease. / Marazzi, Giuseppe; Wajngarten, Mauricio; Vitale, Cristiana; Patrizi, Roberto; Pelliccia, Francesco; Gebara, Otavio; Pierri, Humberto; Ramires, Josè Antonio F; Volterrani, Maurizio; Fini, Massimo; Rosano, Giuseppe M C.
In: International Journal of Cardiology, Vol. 120, No. 1, 09.08.2007, p. 79-84.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease
AU - Marazzi, Giuseppe
AU - Wajngarten, Mauricio
AU - Vitale, Cristiana
AU - Patrizi, Roberto
AU - Pelliccia, Francesco
AU - Gebara, Otavio
AU - Pierri, Humberto
AU - Ramires, Josè Antonio F
AU - Volterrani, Maurizio
AU - Fini, Massimo
AU - Rosano, Giuseppe M C
PY - 2007/8/9
Y1 - 2007/8/9
N2 - Objective: Free fatty acid inhibition with trimetazidine (TMZ) improves myocardial metabolism and myocardial ischemia in patients with coronary artery disease (CAD). Because of its effect on myocardial glucose utilization TMZ may represent a therapeutic option in diabetic patients with CAD. Aim of the present study was to evaluate whether the metabolic effect of TMZ may improve episodes of myocardial ischemia in diabetic patients with CAD. Research design and methods: We assessed the effect of TMZ on 24 h ambulatory ECG monitoring (AEM) in 30 patients (22 males and 8 females, mean (SE) age 67 ± 6.5 years) with NIDDM and ischemic cardiomyopathy. Patients were randomized to receive on top of standard therapy either TMZ (20 mg, tds) or placebo (tds) and were evaluated at baseline and after 6 months. Results: Patients randomized to TMZ or placebo were comparable regarding demographic data, distribution of CAD, and glicated haemoglobin levels. TMZ significantly reduced the number of episodes of transient myocardial ischemia (- 24% compared to baseline, p <0.01; - 27% compared to placebo, p <0.01), and Total Ischemic Burden (- 28% compared to baseline, p <0.01; - 29% compared to placebo, p <0.01). TMZ also significantly reduced the number of silent episodes of myocardial ischemia (- 42% compared to baseline and - 39% compared to placebo, p <0.01) and the time of silent myocardial ischemia/24 h (- 37% compared to baseline and - 35% compared to placebo, p <0.01). No significant changes in heart rate were detected between baseline, placebo and TMZ evaluations. Conclusions: TMZ is effective in reducing silent and symptomatic episodes of transient myocardial ischemia in diabetic patients with CAD on standard anti-anginal therapy.
AB - Objective: Free fatty acid inhibition with trimetazidine (TMZ) improves myocardial metabolism and myocardial ischemia in patients with coronary artery disease (CAD). Because of its effect on myocardial glucose utilization TMZ may represent a therapeutic option in diabetic patients with CAD. Aim of the present study was to evaluate whether the metabolic effect of TMZ may improve episodes of myocardial ischemia in diabetic patients with CAD. Research design and methods: We assessed the effect of TMZ on 24 h ambulatory ECG monitoring (AEM) in 30 patients (22 males and 8 females, mean (SE) age 67 ± 6.5 years) with NIDDM and ischemic cardiomyopathy. Patients were randomized to receive on top of standard therapy either TMZ (20 mg, tds) or placebo (tds) and were evaluated at baseline and after 6 months. Results: Patients randomized to TMZ or placebo were comparable regarding demographic data, distribution of CAD, and glicated haemoglobin levels. TMZ significantly reduced the number of episodes of transient myocardial ischemia (- 24% compared to baseline, p <0.01; - 27% compared to placebo, p <0.01), and Total Ischemic Burden (- 28% compared to baseline, p <0.01; - 29% compared to placebo, p <0.01). TMZ also significantly reduced the number of silent episodes of myocardial ischemia (- 42% compared to baseline and - 39% compared to placebo, p <0.01) and the time of silent myocardial ischemia/24 h (- 37% compared to baseline and - 35% compared to placebo, p <0.01). No significant changes in heart rate were detected between baseline, placebo and TMZ evaluations. Conclusions: TMZ is effective in reducing silent and symptomatic episodes of transient myocardial ischemia in diabetic patients with CAD on standard anti-anginal therapy.
KW - Diabetes mellitus
KW - Myocardial ischema
KW - Prognosis
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=34347215790&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34347215790&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2006.08.082
DO - 10.1016/j.ijcard.2006.08.082
M3 - Article
C2 - 17134770
AN - SCOPUS:34347215790
VL - 120
SP - 79
EP - 84
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
IS - 1
ER -